Non-Small-Cell Lung Cancer (NSCLC)
Standards of care, evolving paradigm and future perspectives

SINGAPORE
20-21 NOVEMBER 2019

Co-Chairs
David Planchard, FR
Ross A. Soo, SG
ESMO PRECEPTORSHIP PROGRAMME
NON-SMALL-CELL LUNG CANCER
Standards of care, evolving paradigm and future perspectives

Singapore
20-21 November 2019

CO-CHAIRS:
David Planchard, France
Ross A. Soo, Singapore

SPEAKERS:
Myung-Ju Ahn, South Korea
Pyng Lee, Singapore
Fabrice Barlesi, France
Tetsuya Mitsudomi, Japan
Byoung Chul Cho, South Korea
Silvia Novello, Italy
Teh-Ying Chou, Taiwan
Ivan Tham, Singapore
Steven C.-H. Kao, Australia

LEARNING OBJECTIVES

• To learn about best clinical practice in the management of Non-Small-Cell Lung Cancer (NSCLC) in the adjuvant, locally advanced and metastatic setting
• To understand the importance of pathology and histoprognostic factors in the management of NSCLC
• To learn about the management of patients after progression, side effects of treatments and the use of targeted agents in NSCLC

ACCREDITATION

The programme of this event has been accredited with 11 ESMO-MORA category 1 points.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

AstraZeneca
MSD

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Chair or Speaker(s)</th>
</tr>
</thead>
</table>
| 09:00-09:10 10’ | Opening and welcome                                                   | David Planchard, FR  
Ross A. Soo, SG |
| 09:10-10:50 100’ | SESSION 1  
Screening, diagnosis and staging | Chair: Steven C.-H. Kao, AU  
Pyng Lee, SG  
Teh-Ying Chou, TW  
Silvia Novello, IT  
Faculty |
| 10:50-11:20 30’ | Coffee break                                                        |  
| 11:20-12:20 60’ | SESSION 2  
Adjuvant therapy                                               | Chair: Silvia Novello, IT  
Silvia Novello, IT  
Ivan Tham, SG |
| 12:20-13:20 30’ | Lunch                                                               |  
| 13:20-14:40 80’ | SESSION 3  
Multi-disciplinary lung tumour board                            | Chair: Ross A. Soo, SG  
Ivan Tham, SG  
Fabrice Barlesi, FR  
Tetsuya Mitsudomi, JP |
| 14:40-15:10 30’ | Coffee break                                                        |  
| 15:10-16:10 60’ | SESSION 4  
Audience cases                                                   | Chairs: David Planchard, FR  
Ross A. Soo, SG  
Faculty |
| 16:10-17:35 85’ | SESSION 5  
Systemic therapy for advanced NSCLC                              | Chair: Tetsuya Mitsudomi, JP  
Myung-Ju Ahn, KR  
Fabrice Barlesi, FR  
Faculty |
| 19:30 | Dinner                                                               |  

Wednesday, 20 November 2019
## Thursday, 21 November 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-11:30</td>
<td><strong>SESSION 6</strong> Targeted therapies</td>
<td>Myung-Ju Ahn, KR</td>
</tr>
<tr>
<td>30’</td>
<td>Systemic therapy for non-oncogene addicted NSCLC</td>
<td>Ross A. Soo, SG</td>
</tr>
<tr>
<td>30’</td>
<td>New treatment options for EGFR + NSCLC</td>
<td>Tetsuya Mitsudomi, JP</td>
</tr>
<tr>
<td>30’</td>
<td>New treatment options for ALK + NSCLC</td>
<td>David Planchard, FR</td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>20’</td>
<td>Targeted therapy beyond EGFR/ALK: BRAF, ROS1</td>
<td>David Planchard, FR</td>
</tr>
<tr>
<td>20’</td>
<td>Targeted therapy beyond EGFR/ALK: RET, MET, NTRK</td>
<td>Byoung Chul Cho, KR</td>
</tr>
<tr>
<td>20’</td>
<td>Discussion</td>
<td>Faculty</td>
</tr>
<tr>
<td>11:30-12:30</td>
<td><strong>SESSION 7</strong> Audience cases</td>
<td>David Planchard, FR</td>
</tr>
<tr>
<td>60’</td>
<td>Participants clinical case discussion (3x20’)</td>
<td>Ross A. Soo, SG</td>
</tr>
<tr>
<td>12:30-13:30</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>13:30-14:50</td>
<td><strong>SESSION 8</strong> Other thoracic tumours and molecular testing</td>
<td>Fabrice Barlesi, FR</td>
</tr>
<tr>
<td>20’</td>
<td>Small-Cell Lung Cancer</td>
<td>Steven C.-H. Kao, AU</td>
</tr>
<tr>
<td>20’</td>
<td>Malignant mesothelioma</td>
<td>Steven C.-H. Kao, AU</td>
</tr>
<tr>
<td>20’</td>
<td>Liquid biopsy</td>
<td>Fabrice Barlesi, FR</td>
</tr>
<tr>
<td>20’</td>
<td>Discussion</td>
<td>Faculty</td>
</tr>
<tr>
<td>14:50-15:00</td>
<td>Conclusion and take home messages</td>
<td>David Planchard, FR</td>
</tr>
<tr>
<td>10’</td>
<td></td>
<td>Ross A. Soo, SG</td>
</tr>
</tbody>
</table>

**Note:** Each 20 minute slot for clinical case discussion includes 10’ case presentation and 10’ Q&A / panel discussion